DOCSLIB.ORG

WO 2012/068299 A9 24 May 2012 (24.05.2012) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2012/068299 A9 24 May 2012 (24.05.2012) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/068299 A9 24 May 2012 (24.05.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/519 (2006.01) A61K 31/53 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/551 7 (2006.0 1) A61P 17/00 (2006.0 1) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US201 1/061062 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 16 November 201 1 (16.1 1.201 1) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/414,334 16 November 2010 (16. 11.2010) US kind of regional protection available): ARIPO (BW, GH, 61/414,348 16 November 2010 (16. 11.2010) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/545,033 7 October 201 1 (07. 10.201 1) us UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant (for all designated States except US): UNIVER¬ DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, SITY OF SOUTHERN CALIFORNIA [US/US]; USC LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Stevens Institute for Innovation, 1150 South Olive Street, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Suite 2300, Los Angeles, CA 90015 (US). GW, ML, MR, NE, SN, TD, TG). (72) Inventors; and Published: (75) Inventors/Applicants (for US only): KAHN, Michael — with declaration under Article 17(2)(a); without abstract; [US/US]; 1101 East Mendocino Street, Altadena, Califor title not checked by the International Searching Authority nia 91001 (US). TEO, Jia-Ling [SG/US]; 1101 East Men docino Street, Altadena, California 91001 (US). MCMIL¬ (48) Date of publication of this corrected version: LAN, Michael [US/US]; 342 North Garfield Avenue, 20 June 2013 Apartment 4, Alhambra, California 91801 (US). ZHAO, Yi [US/US]; 812 Summit Drive, South Pasadena, Califor (15) Information about Corrections: see Notice of 20 June 2013 nia 91030 (US). WU, Yongfeng [CN/US]; 15 18 Prospect Avenue, Apartment 209, San Gabriel, California 91776 Previous Correction: (US). see Notice of 12 July 2012 (74) Agent: DAVISON, Barry L.; Davis Wright Tremaine LLP, 1201 Third Avenue, Suite 2200, Seattle, Washington 98101 (US). < 00 © o o (54) Title: CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS (57) Abstract: CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS FIELD OF THE INVENTION Particular aspects relate generally to aging, and more particularly to the use of CBP/Catenin (e.g., CBP/p-catenin) antagonists (e.g., ICG-001, and alkly and fatty acid ester derivatives thereof, and other compounds disclosed herein) in modulation of symmetric versus asymmetric division for treating aging and aging-related conditions (e.g., wrinkles, hyperpigmentation, dryness, redness, cracking, rosacea, firmness, elasticity, thickness, scarring, appearance). Additional aspects relate generally to the use of said CBP/Catenin (e.g., CBP/p-catenin) antagonists in treating skin related diseases (e.g., wounds, acne, sun damage, effects of aging, treatment of latent infection (e.g., HSV, HPV), viral clearance (epidermal and mucosal tissue), ulcers (diabetic and others), burns, atopic dermatitis, psoriasis, age-related skin conditions including wrinkles, hyperpigmentation, redness, rosacea, dryness, cracking, loss of firmness, loss of elasticity, thinning, and loss of vibrance, etc.) and/or for cosmetic (skin and/or hair) purposes, and in particular aspects for promoting hair growth and/or regrowth and/or pigmentation, and preventing or retarding hair loss (e.g., age-related hair loss or loss of pigmentation). Additional aspects relate to method for increasing adenosine receptor levels in in dermal cells, preferably dermal papilla cells, to facilitate hair growth. Adjunctive and combination therapy embodiments are encompassed. CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to United States Provisional Patent Application Serial Nos. 61/545,033 filed October 07, 2011, 61/414,334 filed November 16, 2010, and 61/414,348 filed November 16, 2010, all incorporated herein by reference in their entirety. BACKGROUND OF THE INVENTION The decision to divide asymmetrically or symmetrically may be the major fundamental intrinsic difference between normal stem and cancer stem cells. The decision to utilize either CBP/catenin or p300/catenin driven transcription, i.e. to divide symmetrically or asymmetrically, appears to be an extremely fundamental event as it is already critical even at the 8-cell stage of embryogenesis. The ultimate decision for a cell to retain potency or initiate differentiation is dependent upon numerous inputs including the activation of different growth factors, cytokines, and hormones and the subsequent activation of different signal transduction complexes and kinase cascades, nutrient levels, oxygen levels, genetic mutations, adhesion to substratum. In the end these multiple pathways must be integrated and funneled down into a simple decision point, i.e., a yes/no binary decision. While it is known how to pharmacologically manipulate the balance of differential catenin coactivator usage (i.e., catenin/CBP versus catenin/p300) in stem/progenitor cell populations, understanding how a cell reads the enormously complex array of information from its environment to arrive at an eventual 0/1 binary decision remains to be understood. SUMMARY OF THE INVENTION According to particular aspects, as disclosed herein, the equilibrium between CBP- mediated and p300-mediated catenin transcription plays a central role in decision to divide asymmetrically or symmetrically by integrating numerous inputs including the activation of different growth factors, cytokines, and hormones and the subsequent activation of different signal transduction complexes and kinase cascades, nutrient levels, oxygen levels, genetic mutations, adhesion to substratum. CBP/catenin (e.g. beta and gamma) antagonists function by regulating human endogenous stem cells and and/or surrounding cell function. Based on animal toxicity studies, and as recognized in the art, these compounds are extremely safe at effective dose levels. Since treating aging and aging-related conditions may require long-term administration, a large safety margin is optimal to physicians and patients alike. According to particular aspects, CBP/catenin (e.g., CBP/p-catenin) antagonists can be used for modulating symmetric versus asymmetric stem cell division for treating aging and aging-related conditions. Particular aspects provide a method for treating aging or a disease of aging or at least one condition or symptom thereof, comprising administering to a subject in need thereof an amount of a CBP/catenin (e.g.,CBP/p-catenin) antagonist sufficient for increasing the number of asymmetric renewing divisions at the expense of symmetric divisions in the stem cell population, wherein a method for treating aging or a disease of aging or at least one symptom thereof is afforded. Additional aspects provide a method for treating hair loss (e.g., preventing hair loss and/or promoting hair growth or regrowth and/or pigmentation (e.g., in aging subjects), comprising administering (e.g., topically or otherwise) to a subject in need thereof an amount of a CBP/catenin (e.g., CBP/p-catenin) antagonist sufficient for increasing the number of symmetric renewing divisions at the expense of symmetric divisions in the relevant stem cell population (e.g., hair follicle or epidermal stem cells), wherein a method for treating hair loss (e.g., preventing hair loss and/or promoting hair growth; e.g., in aging subjects) is afforded. Further aspects provide methods for treating a condition or disease of the skin or at least one symptom thereof, comprising administering to a subject in need thereof an amount of a CBP/catenin (e.g., CBP/p-catenin) antagonist sufficient for treating a condition or disease of the skin or at least one symptom thereof. Exemplary preferred aspects : Particular aspects provide a method for treating aging or an age-related condition, symptom or disease, comprising: identifying a mammalian subject having somatic stem cells for least one tissue compartment or type having an age-related condition, symptom or disease; and administering to the subject a CBP/Catenin (e.g., CBP/p-catenin) antagonist in a manner and amount sufficient to provide for increasing the number of asymmetric renewing divisions relative to, or at the expense of symmetric divisions of the somatic stem cells for the at least one tissue compartment or type, wherein the age related condition, symptom or disease of the tissue compartment or type is decreased or ameliorated, wherein a method for treating aging or an age-related condition, symptom or disease is afforded. In certain aspects, the somatic stem cells for the at least one tissue compartment or type comprise quiescent somatic stem cells, and wherein administering the CBP/p-catenin antagonist comprises CBP/p-catenin antagonist-mediated activation of the quiescent somatic stem cells to enhance or accelerate asymmetric renewing divisions relative to, or at the expense of symmetric divisions among the somatic stem cells of the at least one tissue compartment or type.
Load more

Recommended publications
  • Global Competitiveness in Pharmaceuticals
    Ref. Ares(2014)77485 - 15/01/2014 GLOBAL COMPETITIVENESS IN PHARMACEUTICALS A EUROPEAN PERSPECTIVE* * § ¨ ALFONSO GAMBARDELLA , LUIGI ORSENIGO , FABIO PAMMOLLI November 2000 Report prepared for the Enterprise Directorate-General of the European Commission * The authors wish to thank G. Baio, N. Lacetera, L. Magazzini, M. Mariani, R. Pammolli, and M. Riccaboni for skillfull research assistance. * Sant’Anna School of Advanced Studies, Pisa, [email protected]. § Bocconi University, Milan, [email protected]. ¨ Faculty of Economics Richard M. Goodwin, University of Siena, [email protected]. Enterprise Papers Enterprise Papers are a mix of policy papers, sector-specific studies, and a combination of both. Written by the staff of the Enterprise Directorate-General, or by experts working in association with them, they aim to raise awareness of enterprise policy issues and stimulate debate. These papers do not necessarily reflect the opinion or position of the European Commission. Occasional ‘special editions’ may carry communications, conference proceedings, and reports to the Council. This report was prepared for the Enterprise Directorate-General by Alfonso Gambardella, Luigi Orsenigo and Fabio Pammolli. For further information, contact European Commission Enterprise Directorate-General Information and communication unit Rue de la Loi/ Wetstraat 200 B-1049 Brussels Fax: (32-2) 299 1926 To request copies, fax (32-2) 296 9930. E-mail: [email protected] A great deal of additional information on the European Union is available on the internet. It can be accessed through the Europa server (http://europa.eu.int). Luxembourg: Office for Official Publications of the European Communities, 2001 ISBN 92-894-1071-X © European Communities, 2001 Reproduction is authorised provided the source is acknowledged.
    [Show full text]
  • “Analysis of SCM: a Case Study of Wyeth Pharmaceutical Company”
    “Analysis of SCM: A case study of Wyeth Pharmaceutical company” Submitted by: Shahzad Ali Rajpar Supervised by: Mr. Muhammad Amir Adam Program: MBA FALL 2010 National University of Computer & Emerging Science Management Science Department, Karachi, Campus Page | 1 Acknowledgments Thanks to Allah the All Merciful the all Benevolent for providing me the strength, courage, direction and skills to learn, acquire knowledge, and the ability to accept and meet challenges. Second I would like to thank all those people who have helped me in performing this research study, especially Mr. Aftab Amie Siddiqui manager planning and warehouse, Wyeth Pharmaceutical Limited Pakistan. I would like to express my sincere gratitude to my supervisor Mr. Mohammad Amir Adam for providing me his precious time, guidance, and instructions all along in order to materialize my content for the project report. I would also like to thank the FYP Coordinator Mr. Zaki Rashidi for his assistance and guidance for the research project. I am also thankful to my parents who accommodated me during those long hours of work in my project development and all the friends and colleagues who helped me out in my times of weakness and encouraged me. I am hopeful that the effort will be fruitful for the students to come in FAST after us. Once again, I am very thankful to all people who have been involved in this project report directly or indirectly. Page | 2 Table of Contents Acknowledgments ............................................................................................. 2 Table of Contents .............................................................................................. 3 CHAPTER 1 “INTRODUCTION” ........................................................................... 6 1.1 Supply chain management. ..................................................................... 6 1.2 Evolution of supply chain management.
    [Show full text]
  • PHARMACEUTICAL September 2009
    PHARMACEUTICALS September 2009 PHARMACEUTICAL September 2009 The focus of this presentation is to discuss… Market overview Policy Key trends and drivers Key players Key opportunities 2 MARKET OVERVIEW Pharmaceutical September 2009 Indian pharmaceutical market — US$ 7.3 billion opportunity • India is among the fastest growing pharmaceutical markets in the world. • The pharmaceutical market was worth US$ 16.6 billion in 2007–08; the domestic retail market is expected to cross the US$ 10 billion mark in 2010 and reach an estimated US$ 12 billion to US$ 13 billion by 2012. Domestic pharma retail market Break up of Indian pharma industry 16 13.6 13.4 14 12 10.1 10 7.7 8 5.4 4.8 6 3.9 4.1 46% (US$ million) (US$ 4 2.5 2.6 54% 1.4 2 1.1 0 2002-03 2005-06 2007-08E 2012-13P Domestic Formulation Consumption (DFC) Domestic Formulation Consumption (DFC) Total exports Formulation exports Bulk drug export Source: Pharmaceuticals: industry profile, Dec 2008, CRIS INFAC Source: Pharmaceuticals: industry profile, Dec 2008, CRIS INFAC 3 MARKET OVERVIEW Pharmaceutical September 2009 Indian pharmaceutical market — US$ 7.3 billion opportunity • The outsourcing opportunity is set to grow to Forecasted Indian pharmaceutical retail market in US$ bn US$ 53 billion in 2010 from US$ 26 billion in 2006. • Retail sales of pharmaceuticals were US$ 7.7 billion in 2007–08. • Domestic consumption accounted for nearly 46 per cent and exports for the remaining 54 per cent of total industry revenues. Source: Compiled from industry sources 4 MARKET OVERVIEW Pharmaceutical September 2009 Anti-infectives — largest therapeutic category • The anti-infectives segment was the highest contributor (18 per cent) to total domestic sales in 2007–08.
    [Show full text]
  • Directory of Recognised In-House R&D Units
    DIRECTORY OF RECOGNISED IN-HOUSE R&D UNITS 2011 DEPARTMENT OF SCIENTIFIC & INDUSTRIAL RESEARCH MINISTRY OF SCIENCE AND TECHNOLOGY NEW DELHI Sl.No Registration Name and Address of the Firm Location of R&D Unit Recognition Number Valid Upto 1 TU/IV-RD/3105 20 Microns Nano Minerals Limited 11, GIDC Estate, Waghodia, 31.03.2013 307-308, Arundeep Complexes.Race Dist. Vadodrara, Gujrat Course ,Vadodara-390007, Gujarat 2 TU/IV-RD/3351 A.J Organica Pvt. Ltd. Plot . No 8 Survey No. 288 31.03.2014 Plot . No 8Survey No. 288,Raisoni Raisoni Indsutrial Estate Mann Indsutrial Estate Mann Taluka Mulshi Taluka Mulshi Hinjewadi Phase IIPune- 411057 3 TU/IV-RD/3153 Aadhaar Seeds Pvt. Ltd. Raja Bollaram (Village), 31.03.2014 1-5-12/2/2, New Maruthi Nagar, Medchal (Mandal), R. R. Dist. Kothapet, Hyderabad – 500 035 (AP) 4 TU/IV-RD/2141 Aarti Drugs Ltd. (i) Plot No.198, MIDC Tarapur, 31.03.2014 D-109, Gr. Floor, Mahendra Indl. Vill. Pamtembhi, Tal. Palghar, EstateRoad No. 29, Sion (E)Mumbai - Dist. Thane (ii) G-60, MIDC, 400 022 Tarapur, Tal. Palghar, Dist. Thane 5 TU/IV-RD/2193 Aarti Industries Ltd. Plot No.801, 801/23, GIDC 31.03.2012 Udyog Kshetra, 2nd FloorMulund- Estate, Phase III, Vapi, Dist. Goregaon Link Road, Mulund Valsad, Gujarat (W)Mumbai-400080 6 TU/IV-RD/637 Abbott India Ltd. L-18, Verna Ind. Area, Verna, 31.03.2013 3-4, Corporate ParkSion-Trombay Salcette, Goa Road,Chembur,Mumbai- 400071 7 TU/IV-RD/3180 ABC Genomics (India) Pvt. Ltd.
    [Show full text]
  • Federal Register/Vol. 77, No. 115/Thursday, June 14, 2012
    Federal Register / Vol. 77, No. 115 / Thursday, June 14, 2012 / Notices 35691 TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2012, THROUGH MARCH 31, 2012—Continued PMA No., Docket No. Applicant Trade name Approval date P060008.S046, FDA–2012–M–0210 ... Boston Scientific Corp ......................... TAXUS Liberte´ Paclitaxel-Eluting Cor- February 22, 2012. onary Stent System (Monorail and Over-The-Wire Delivery Systems). P030025.S086, FDA–2012–M–0209 ... Boston Scientific Corp ......................... TAXUS Express2 Paclitaxel-Eluting February 22, 2012. Coronary Stent System (Monorail and Over-The-Wire Delivery Sys- tems). P110023, FDA–2012–M–0221 ............ ev3, Inc ................................................ Everflex Self-Expanding Peripheral March 7, 2012. Stent System (Everflex). P070004, FDA–2012–M–0250............ Sientra, Inc.......................................... SIENTRA Silicone Gel Breast Im- March 9, 2012. plants. II. Electronic Access LOCATION: The meeting will be held at submissions. In the process of Persons with access to the Internet the FDA White Oak Campus, 10903 considering these changes, FDA has may obtain the documents at http:// New Hampshire Ave., Bldg. 31 previously made available for comment www.fda.gov/MedicalDevices/ Conference Center, Great Room 1503, versions of documents that support ProductsandMedicalProcedures/ Silver Spring, MD 20993. The following making regulatory submissions in DeviceApprovalsandClearances/ link contains public meeting attendee electronic format using the (eCTD) information as well as frequently asked PMAApprovals/default.htm and http:// specifications. These draft documents questions and answers regarding public www.fda.gov/MedicalDevices/ represented FDA’s major updates to meetings at White Oak: http:// ProductsandMedicalProcedures/ Module 1 of the eCTD based on www.fda.gov/AboutFDA/ DeviceApprovalsandClearances/ previous comments.
    [Show full text]
  • REGISTER of SPONSORS (Tiers 2 & 5 and Sub Tiers Only)
    REGISTER OF SPONSORS (Tiers 2 & 5 and Sub Tiers Only) DATE: 09-January-2017 Register of Sponsors Licensed Under the Points-based System This is a list of organisations licensed to sponsor migrants under Tiers 2 & 5 of the Points-Based System. It shows the organisation's name (in alphabetical order), the sub tier(s) they are licensed for, and their rating against each sub tier. A sponsor may be licensed under more than one tier, and may have different ratings for each tier. No. of Sponsors on Register Licensed under Tiers 2 and 5: 29,794 Organisation Name Town/City County Tier & Rating Sub Tier ?What If! Ltd London Tier 2 (A rating) Tier 2 General Tier 2 (A rating) Intra Company Transfers (ICT) @ Home Accommodation Services Ltd London Tier 2 (A rating) Tier 2 General Tier 5 (A rating) Creative & Sporting ]performance s p a c e [ london london Tier 5 (A rating) Creative & Sporting 01 Telecom Limited Brighton Tier 2 (A rating) Tier 2 General 0-two Maintenance London Tier 2 (A rating) Tier 2 General 1 Stop Print Ltd Ilford Tier 2 (A rating) Tier 2 General 1 Tech LTD London Tier 2 (A rating) Tier 2 General 10 Europe Limited Edinburgh Tier 2 (A rating) Tier 2 General Tier 2 (A rating) Intra Company Transfers (ICT) 10 GROUP LTD T/A THE 10 GROUP LONDON Tier 2 (A rating) Tier 2 General 10 Minutes With Limited London Tier 2 (A rating) Tier 2 General Page 1 of 1952 Organisation Name Town/City County Tier & Rating Sub Tier 1000heads Ltd London Tier 2 (A rating) Tier 2 General 1000mercis LTD London Tier 2 (A rating) Tier 2 General 100Starlings Ltd
    [Show full text]
  • Drugs and Pharmaceuticals "D".Pdf
    Drugs and Pharmaceuticals “D” NDC Code Description Manufacturer Basic Category UM 63323-0127-10 DACARBAZINE PR 100MG 10VL APP-AMER PHARM PTNRS CT Injectables/RX Drugs 63323-0128-20 DACARBAZINE PR 200MG 10VL APP-AMER PHARM PTNRS CT Injectables/RX Drugs 58768-0727-15 DACRIOSE 15ML NVR DR NOVARTIS OPHTHALMICS EA OTC 58768-0727-20 DACRIOSE DR 120ML NOVARTIS OPHTHALMICS EA OTC 10135-0115-01 DAILY MULTIPLE VIT RED 100 MARLEX PHARMACEUTICALS EA OTC 63739-0274-01 DAILY MULTI/IRON 750UD INST SKY PHARMACEUTICALS BX OTC 63739-0068-01 DAILY MULTIVITAMIN 750UD SKY PHARMACEUTICALS EA OTC INST 63739-0274-03 DAILY MULTIVTMN/IRON 25x30 SKY PHARMACEUTICALS BX OTC UDPC 00536-0410-59 DAILY VIT HOMOGEN 8oz SR WATSON LABS EA OTC 00536-3546-10 DAILY VIT IRON 1000 WAT TB WATSON LABS EA OTC 00536-3546-01 DAILY-VIT/IRON 100 WAT WATSON LABS EA OTC 00436-0946-16 DAKINS FS 0.5% 480ML NR SL CENTURY PHARMACEUTICALS EA OTC 50383-0624-16 DALYVITE 16oz SL HI-TECH PHARMACAL EA OTC COMPANY 49938-0101-01 DAPSONE 100MG 100 TB JACOBUS PHARMACEUTICAL EA Injectables/RX Drugs CO. INC 49938-0102-01 DAPSONE 25MG 100 TB JACOBUS PHARMACEUTICAL EA Injectables/RX Drugs CO. INC 00173-0201-55 DARAPRIM 25MG 100 GLX TB GLAXOSMITHKLINE EA Injectables/RX Drugs 00002-0363-02 DARVOCENT-N 100 TB 100 C4 TB A. A. I PHARMACEUTICALS EA Drug, DEA Schedule 00002-0363-33 DARVOCENT-N 100 TB 100UD C4 A. A. I PHARMACEUTICALS EA Drug, DEA Schedule TB 00002-0803-02 DARVON CP 65MG 100 C4 CP A.
    [Show full text]
  • Redacted Craig Mccann Opioid MDL ARCOS Report.Pdf
    Case: 1:17-md-02804-DAP Doc #: 1999-13 Filed: 07/25/19 1 of 154. PageID #: 264837 Confidential - Subject to Protective Order IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION IN RE NATIONAL : MDL No. 2804 PRESCRIPTION OPIATE : CASE NO. 17-MD-2804 LITIGATION : (DAP) : EXPERT REPORT OF CRAIG J. MCCANN, PH.D., CFA March 25, 2019 Case: 1:17-md-02804-DAP Doc #: 1999-13 Filed: 07/25/19 2 of 154. PageID #: 264838 Confidential - Subject to Protective Order Table of Contents I. Qualifications and Remuneration ..................................................... - 1 - A. Qualifications ......................................................................... - 1 - B. Remuneration ......................................................................... - 2 - II. Materials Reviewed .......................................................................... - 2 - III. Assignment ....................................................................................... - 4 - IV. Summary of Opinions ....................................................................... - 4 - V. ARCOS Data .................................................................................... - 7 - A. Receipt of ARCOS Data from the DEA ................................ - 7 - B. ARCOS Data Fields Produced by DEA ................................. - 9 - 1. Seller DEA Number .................................................................. - 11 - 2. Seller Business Activity ............................................................ - 12
    [Show full text]
  • Torreya In-Depth Study—The Future of the Global Pharmaceutical Industry
    The Future of the Global Pharmaceutical Industry October 2017 Ta b l e o f Co n te n t s Section Page 1. Executive Summary 3 2. Pharmaceutical Sector Has Grown Rapidly in the Last Century 7 - Widespread concerns about the sector today 8 - Thousandfold increase in value of companies in sector since 1920s 10 3. Pharmaceutical Sector Will Triple in Size in the Next 40 Years 12 - Pharmaceutical consumption econometrically close related to GDP growth 14 - Based upon expected GDP growth, the pharma sector will likely triple in size by 2060 19 4. Total Value of the Pharmaceutical Sector Today over $5 Trillion 20 - Total revenue in the pharma sector around $1.1 trillion in 2017 23 - Total value of companies in sector over $5 trillion. Pharma one of the world’s largest sectors 24 5. Pharma Will Be Positively Impacted by Growth in Rare Disease Drugs and China 27 - Cost controls widespread and likely to continue. Major impact on Europe market 28 - Rare disease pharma sector has grown in value by 1300% since 2000. To continue growing fast 37 - China to become a close #2 to the U.S. market in time. Dramatic growth to continue 49 6. Innovations in Inflammation Control, Nucleic Acids and Implantables Will Transform Industry 55 - Better Manufacture Will Facilitate Dramatic Growth in Peptide Therapeutics 56 - Control of Inflammation May Substantially Reduce Mortality from Cancer & Heart Disease 61 - Nucleic Acid Therapeutics a Source of Substantial Future Growth 65 - Cell Therapy is Becoming Mainstream in the Pharmaceutical Industry 70 - Implantables and Electroceuticals Will Redefine Therapeutic Sector 74 7.
    [Show full text]
  • Final Report Ventura County Medical Center 340B Drug Pricing Program
    Ventura County Grand Jury 2017 - 2018 Final Report Ventura County Medical Center 340B Drug Pricing Program April 26, 2018 This page intentionally blank Ventura County 2017 – 2018 Grand Jury Final Report Ventura County Medical Center 340B Drug Pricing Program Summary The 2017-2018 Ventura County Grand Jury (Grand Jury) opened an investigation after receiving a complaint about the Ventura County Medical Center’s (VCMC) 340B Drug Pricing Program (340B program). The 340B program requires pharmaceutical companies to provide prescription drugs at significant discounts to hospitals and clinics serving large numbers of low-income patients. In July 2015 an audit of VCMC was conducted by the federal Health Resources and Services Administration (HRSA). The audit discovered that VCMC received duplicate discounts on medications in the 340B program. A total of 107 pharmaceutical companies were affected by the duplicate discount billing. The total duplicate discounts were in excess of $3 million. The Grand Jury concluded there was inadequate oversight of the VCMC 340B program prior to the HRSA audit. This resulted in VCMC being required to reimburse pharmaceutical companies at least $861,000 and potentially as much as $1.6 million. The Grand Jury concluded while VCMC conducts its own in-house audits of the 340B program, more critical audits should be conducted by an independent outside party. The Grand Jury recommends VCMC consider bringing in outside resources with extensive 340B program experience to assist in the supervision of a corrective action plan. The Grand Jury also recommends VCMC request the Ventura County Auditor-Controller conduct regular compliance audits of the 340B program.
    [Show full text]
  • Global Competitiveness in Pharmaceuticals: a European Perspective
    Munich Personal RePEc Archive Global Competitiveness in Pharmaceuticals: A European Perspective Gambardella, Alfonso and Orsenigo, Luigi and Pammolli, Fabio IMT Institute For Advanced Studies, Lucca 1 November 2000 Online at https://mpra.ub.uni-muenchen.de/15965/ MPRA Paper No. 15965, posted 30 Jun 2009 09:08 UTC - GLOBAL COMPETITIVENESS IN PHARMACEUTICALS A EUROPEAN PERSPECTIVE* ∗ ♣ ♦ ALFONSO GAMBARDELLA , LUIGI ORSENIGO , FABIO PAMMOLLI November 2000 Report Prepared for the Directorate General Enterprise of the European Commission * The authors wish to thank G. Baio, N. Lacetera, L. Magazzini, M. Mariani, R. Pammolli, and M. Riccaboni for skillfull research assistance. ∗ Sant’Anna School of Advanced Studies, Pisa, [email protected]. ♣ Bocconi University, Milan, [email protected]. ♦ Faculty of Economics Richard M. Goodwin, University of Siena, [email protected]. I. INTRODUCTION............................................................................................... 2 II. STRUCTURAL INDICATORS IN THE EU, USA, AND JAPAN.................. 11 III. THE EUROPEAN AND US MULTINATIONALS: COMPARATIVE PERFORMANCE ...................................................................................................... 25 IV. R&D AND INNOVATION AS SOURCES OF COMPETITIVE ADVANTAGES.......................................................................................................... 36 IV.1 THE DIVISION OF INNOVATIVE LABOUR IN PHARMACEUTICALS ....................... 36 IV.2 THE US AS AN INCREASINGLY PREFERRED LOCATION FOR
    [Show full text]
  • Fasttrack Bwus Wrr 15 2 Abs
    Wound Repair and Regeneration Wound Healing Society Tentative Schedule of Abstract Presentations April 28 to May 1, 2007 Tampa Convention Center SUNDAY, APRIL 29, 2007 Oxygen/Oxidative Stress Session Number: 46 Burn/Fetal Wounds/Acute Wounds Monday, April 30, 2007, 4:00 to 6:00 pm Session Number: 28 Abstracts 57–65 Sunday, April 29, 2007, 5:00 to 7:00 pm Abstracts 1–10 TUESDAY, MAY 1, 2007 Bioengineering/Extracellular Matrix Angiogenesis Session Number: 29 Session Number: 51 Sunday, April 29, 2007, 5:00 to 7:00 pm Tuesday, May 1, 2007, 7:30 to 9:30 am Abstracts 11–19 Abstracts 66–74 Fibrosis/Scar Inflammation Session Number: 30 Session Number: 52 Sunday, April 29, 2007, 5:00 to 7:00 pm Tuesday, May 1, 2007, 7:30 to 9:30 am Abstracts 20–29 Abstracts 75–84 Clinical Treatments Session Number: 53 MONDAY, APRIL 30, 2007 Tuesday, May 1, 2007, 7:30 to 9:30 am Abstracts 85–93 Young Investigator Awards Session Number: 41 ORAL-POSTER PRESENTATIONS: Monday, April 30, 2007, 2:30 to 3:45 pm Abstracts 30–37 Blue Ribbon Posters Sunday, April 29, 2007, 7:00 to 8:30 am Gene Therapy/Growth Factors Abstracts 94–102 Session Number: 44 Monday, April 30, 2007, 4:00 to 6:00 pm Abstracts 103–149 (Posters will be on display at all Abstracts 38–47 times) Even Numbered Poster Oral Presentations Chronic Wounds Sunday, April 29, 2007, 7:00 to 8:30 am Session Number: 45 Monday, April 30, 2007, 4:00 to 6:00 pm Odd Numbered Poster Oral Presentations Abstracts 48–56 Monday, April 30, 7:00 to 8:30 am Wound Rep Reg (2007) 15 A13 c 2007 by the Wound Healing Society A13 Wound Repair and Regeneration Abstracts Wound Healing Society Tentative Schedule of Abstract Presentations April 28 to May 1, 2007 Tampa Convention Center SUNDAY, APRIL 29, 2007 2 SPECTRAL RESOLUTION OF WATER CONCENTRATION Burn/Fetal Wounds/Acute Wounds (EDEMA) IN BURNED TISSUE Session Number: 28 K.M.
    [Show full text]